Brugada syndrome associated adolescent loperamide abuse

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We present the case of a 14-year-old boy with obesity, hypertension, and chronic loperamide abuse who presented to our facility with symptoms of opioid withdrawal and type 1 Brugada pattern o electrocardiogram. He was treated for anxiety and withdrawal. There were no documented dysrhythmias. His Brugada pattern resolved by hospital day 5 and remained resolved 12 days postadmission. Genetic testing revealed a heterozygous missense mutation in the SCN5A gene (c. 5038GA, p. Ala1680Thr), which has been reported in association with Brugada syndrome. To date, there are no published reports of pediatric loperamide use associated with a Brugada pattern on an electrocardiogram. We propose that chronic loperamide use unmasked the electrocardiographic phenotype associated with his gene mutation.

Original languageEnglish (US)
Article numbere20181423
JournalPediatrics
Volume142
Issue number4
DOIs
StatePublished - Oct 1 2018

Fingerprint

Loperamide
Brugada Syndrome
Electrocardiography
Substance Withdrawal Syndrome
Genetic Testing
Missense Mutation
Opioid Analgesics
Genes
Anxiety
Obesity
Pediatrics
Hypertension
Phenotype
Mutation

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{a4846dd1e76a4a1aab4b721d12f94efe,
title = "Brugada syndrome associated adolescent loperamide abuse",
abstract = "We present the case of a 14-year-old boy with obesity, hypertension, and chronic loperamide abuse who presented to our facility with symptoms of opioid withdrawal and type 1 Brugada pattern o electrocardiogram. He was treated for anxiety and withdrawal. There were no documented dysrhythmias. His Brugada pattern resolved by hospital day 5 and remained resolved 12 days postadmission. Genetic testing revealed a heterozygous missense mutation in the SCN5A gene (c. 5038GA, p. Ala1680Thr), which has been reported in association with Brugada syndrome. To date, there are no published reports of pediatric loperamide use associated with a Brugada pattern on an electrocardiogram. We propose that chronic loperamide use unmasked the electrocardiographic phenotype associated with his gene mutation.",
author = "Stefek, {Bryan P.} and Timothy Wolfe and Mark Cohen",
year = "2018",
month = "10",
day = "1",
doi = "10.1542/peds.2018-1423",
language = "English (US)",
volume = "142",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4",

}

Brugada syndrome associated adolescent loperamide abuse. / Stefek, Bryan P.; Wolfe, Timothy; Cohen, Mark.

In: Pediatrics, Vol. 142, No. 4, e20181423, 01.10.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brugada syndrome associated adolescent loperamide abuse

AU - Stefek, Bryan P.

AU - Wolfe, Timothy

AU - Cohen, Mark

PY - 2018/10/1

Y1 - 2018/10/1

N2 - We present the case of a 14-year-old boy with obesity, hypertension, and chronic loperamide abuse who presented to our facility with symptoms of opioid withdrawal and type 1 Brugada pattern o electrocardiogram. He was treated for anxiety and withdrawal. There were no documented dysrhythmias. His Brugada pattern resolved by hospital day 5 and remained resolved 12 days postadmission. Genetic testing revealed a heterozygous missense mutation in the SCN5A gene (c. 5038GA, p. Ala1680Thr), which has been reported in association with Brugada syndrome. To date, there are no published reports of pediatric loperamide use associated with a Brugada pattern on an electrocardiogram. We propose that chronic loperamide use unmasked the electrocardiographic phenotype associated with his gene mutation.

AB - We present the case of a 14-year-old boy with obesity, hypertension, and chronic loperamide abuse who presented to our facility with symptoms of opioid withdrawal and type 1 Brugada pattern o electrocardiogram. He was treated for anxiety and withdrawal. There were no documented dysrhythmias. His Brugada pattern resolved by hospital day 5 and remained resolved 12 days postadmission. Genetic testing revealed a heterozygous missense mutation in the SCN5A gene (c. 5038GA, p. Ala1680Thr), which has been reported in association with Brugada syndrome. To date, there are no published reports of pediatric loperamide use associated with a Brugada pattern on an electrocardiogram. We propose that chronic loperamide use unmasked the electrocardiographic phenotype associated with his gene mutation.

UR - http://www.scopus.com/inward/record.url?scp=85054076494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054076494&partnerID=8YFLogxK

U2 - 10.1542/peds.2018-1423

DO - 10.1542/peds.2018-1423

M3 - Article

C2 - 30254039

AN - SCOPUS:85054076494

VL - 142

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4

M1 - e20181423

ER -